Modelling and simulation as research tools in paediatric drug development
about
Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation.Modeling and simulation as a tool to bridge efficacy and safety data in special populations.Integration of PKPD relationships into benefit-risk analysisRandomized controlled trials of antibiotics for neonatal infections: a systematic reviewPopulation pharmacokinetics of deferiprone in healthy subjects.Clinical trials in childrenEffect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenPharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing.Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtrationExternal Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings.Optimizing drug development of anti-cancer drugs in children using modelling and simulation.Pediatric Biopharmaceutical Classification System: Using Age-Appropriate Initial Gastric Volume.Integration of pharmacogenetics and pharmacogenomics in drug development: implications for regulatory and medical decision making in pediatric diseases.Physiologically based pharmacokinetic (PBPK) modeling in children.Methods for pharmacokinetic analysis in young children.Dosage individualization in children: integration of pharmacometrics in clinical practice.Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling.How to optimise drug study design: pharmacokinetics and pharmacodynamics studies introduced to paediatricians.A model-based approach for the evaluation of once daily dosing of lamivudine in HIV-infected children.Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV.Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years.A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates.Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug.Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research.Dosing rationale for fixed-dose combinations in children: shooting from the hip?Bottom-up Meets Top-down: Complementary Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling for Regulatory Approval of a Dosing Algorithm of Valganciclovir in Very Young Children.Model Informed Pediatric Development Applied to Bilastine: Ontogenic PK Model Development, Dose Selection for First Time in Children and PK Study Design.A predictive pharmacokinetic/pharmacodynamic model of fentanyl for analgesia/sedation in neonates based on a semi-physiologic approach.Discontinuities and disruptions in drug dosage guidelines for the paediatric population.
P2860
Q27312881-006D4F02-D99C-4CA4-A057-3CF869EE3C5CQ30654043-F7C81B88-6581-4FAA-AEB0-0B3C8497B02FQ30671571-F5C18722-938C-4ACF-B21F-8131E395E2C0Q34619963-D313E9A0-16DC-4580-97AD-727E4A7A7157Q34635568-93331A12-4626-4B50-A390-463BA59B7601Q35135928-D0117D06-D88D-40D3-869C-405F547D3C33Q36322918-89AE38AC-438A-4F4B-B8B7-7A81369B5A43Q36410129-D3B72A54-0429-4786-BC4D-78B64E96A610Q36568925-C5B1A784-C3C4-4A21-AF20-B8DD002CACD6Q36729959-89D59061-3A64-468D-BCA7-5CF0B894B412Q36987975-B7D24D0B-DF84-4A79-A8FC-B0F5664C59A6Q37600374-35B7B383-63FF-4335-9845-58DFF7AD76AAQ37874869-96D18FA9-1C57-4060-9695-CE76AAC960ACQ38016332-991662E4-A24B-40EF-B8CD-2958B66D39BDQ38187157-BCF33E27-7851-4193-A830-00A1BFD8A9C1Q38240055-EE277183-CB2C-4BEA-A053-1A1B2B7060CDQ38857191-E5D74622-F073-4091-94F0-0231081CB442Q38965300-07CA8343-38A2-4EC9-8E66-2B8201931002Q39051618-52867AFD-14F4-4867-AE8F-623D8207A027Q39064765-506F2360-FBC0-41B0-83E6-F8A76AE71138Q39377048-1AD5F5AF-8222-47E5-AE51-98E1BA1796FCQ41477321-F9B679FB-4C81-42E8-98DA-B78BF68D342AQ41975490-77AAA8D3-6FDA-4D57-AD1D-1B62F8E3C5FEQ42905874-4A8FE1D0-0AD1-44B3-9C0B-262AD35E7334Q44677507-2EF1CC51-CCAB-48F6-8359-F3FA4612135EQ44781273-2B194814-217F-4521-AB6C-5369EC9E7A8FQ47877945-0F1E6BAD-E06B-4B7D-81BE-7BFC0B6E87EFQ48010349-B2EA759F-8DCF-4722-8F95-26C16B7C3B66Q48092185-A34EC2A2-19B3-4C40-A6DA-D0C47385A759
P2860
Modelling and simulation as research tools in paediatric drug development
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Modelling and simulation as research tools in paediatric drug development
@ast
Modelling and simulation as research tools in paediatric drug development
@en
Modelling and simulation as research tools in paediatric drug development
@nl
type
label
Modelling and simulation as research tools in paediatric drug development
@ast
Modelling and simulation as research tools in paediatric drug development
@en
Modelling and simulation as research tools in paediatric drug development
@nl
prefLabel
Modelling and simulation as research tools in paediatric drug development
@ast
Modelling and simulation as research tools in paediatric drug development
@en
Modelling and simulation as research tools in paediatric drug development
@nl
P2860
P1476
Modelling and simulation as research tools in paediatric drug development
@en
P2093
Francesco Bellanti
Oscar Della Pasqua
P2860
P2888
P356
10.1007/S00228-010-0974-3
P407
P478
67 Suppl 1
P577
2011-05-01T00:00:00Z
P5875
P6179
1046164259